NO327609B1 - Svekkede muterte bakterier anvendelige i vaksiner. - Google Patents
Svekkede muterte bakterier anvendelige i vaksiner. Download PDFInfo
- Publication number
- NO327609B1 NO327609B1 NO20004781A NO20004781A NO327609B1 NO 327609 B1 NO327609 B1 NO 327609B1 NO 20004781 A NO20004781 A NO 20004781A NO 20004781 A NO20004781 A NO 20004781A NO 327609 B1 NO327609 B1 NO 327609B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- bacteria
- salmonella
- mutation
- vaccine
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 67
- 229960005486 vaccine Drugs 0.000 title claims abstract description 45
- 230000002238 attenuated effect Effects 0.000 title abstract description 12
- 230000035772 mutation Effects 0.000 claims abstract description 51
- 101150073640 ompF gene Proteins 0.000 claims abstract description 23
- 101150110245 ompC gene Proteins 0.000 claims abstract description 22
- 241000588724 Escherichia coli Species 0.000 claims abstract description 21
- 101150042732 aroC gene Proteins 0.000 claims abstract description 20
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 11
- 230000002441 reversible effect Effects 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 238000012217 deletion Methods 0.000 claims description 34
- 230000037430 deletion Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 13
- 241000607142 Salmonella Species 0.000 claims description 12
- 101150037081 aroA gene Proteins 0.000 claims description 9
- 101150018266 degP gene Proteins 0.000 claims description 9
- 101150007310 htrA gene Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 7
- 101150040872 aroE gene Proteins 0.000 claims description 7
- 241001167018 Aroa Species 0.000 claims description 6
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 claims description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 101150102858 aroD gene Proteins 0.000 claims description 4
- 101150108612 aroQ gene Proteins 0.000 claims description 4
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 4
- 101100163490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) aroA1 gene Proteins 0.000 claims description 3
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims description 3
- 241000588832 Bordetella pertussis Species 0.000 claims description 3
- 241000589562 Brucella Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 claims description 3
- 241000607598 Vibrio Species 0.000 claims description 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 3
- -1 cya Proteins 0.000 claims description 3
- 101150002054 galE gene Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 101150044129 nirB gene Proteins 0.000 claims description 3
- 101150028857 phoP gene Proteins 0.000 claims description 3
- 101150008241 purT gene Proteins 0.000 claims description 3
- 241000589567 Brucella abortus Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241001138501 Salmonella enterica Species 0.000 claims description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 2
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 2
- 229940056450 brucella abortus Drugs 0.000 claims description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 18
- 229920001817 Agar Polymers 0.000 description 41
- 239000008272 agar Substances 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 229930006000 Sucrose Natural products 0.000 description 26
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 26
- 239000005720 sucrose Substances 0.000 description 26
- 239000002609 medium Substances 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 229960000723 ampicillin Drugs 0.000 description 15
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 15
- 101150091444 ompR gene Proteins 0.000 description 15
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 description 14
- 101150075472 ycf27 gene Proteins 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- AVKUERGKIZMTKX-BBGACYKPSA-N (2s,5r,6r)-6-[[(2s)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-BBGACYKPSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000006154 MacConkey agar Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000006151 minimal media Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001625930 Luria Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700028353 OmpC Proteins 0.000 description 3
- 108700006385 OmpF Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 108010001506 colonization factor antigens Proteins 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010039447 salmonellosis Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 101100505882 Arabidopsis thaliana GSTF12 gene Proteins 0.000 description 2
- 101100497411 Escherichia coli csoB gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 101710082149 Major fimbrial subunit Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 101150038013 PIR gene Proteins 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- 102000017033 Porins Human genes 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 101150025220 sacB gene Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101100172469 Escherichia coli (strain K12) envZ gene Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- 241000709727 Human poliovirus 3 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 108010036940 Levansucrase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940050459 ciprofloxacin 500 mg Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 101150092055 envZ gene Proteins 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 101150047779 ompB gene Proteins 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
- C12N15/03—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806449.6A GB9806449D0 (en) | 1998-03-25 | 1998-03-25 | Attenuated bacteria useful in vaccines |
PCT/GB1999/000935 WO1999049026A1 (en) | 1998-03-25 | 1999-03-25 | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20004781D0 NO20004781D0 (no) | 2000-09-25 |
NO20004781L NO20004781L (no) | 2000-11-08 |
NO327609B1 true NO327609B1 (no) | 2009-08-31 |
Family
ID=10829280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20004781A NO327609B1 (no) | 1998-03-25 | 2000-09-25 | Svekkede muterte bakterier anvendelige i vaksiner. |
Country Status (19)
Country | Link |
---|---|
US (1) | US6902906B1 (xx) |
EP (1) | EP1066376B1 (xx) |
JP (1) | JP4516210B2 (xx) |
KR (1) | KR100628657B1 (xx) |
AT (1) | ATE296881T1 (xx) |
AU (1) | AU763683B2 (xx) |
CA (1) | CA2323576C (xx) |
CZ (1) | CZ301520B6 (xx) |
DE (1) | DE69925585T2 (xx) |
DK (1) | DK1066376T3 (xx) |
ES (1) | ES2244182T3 (xx) |
GB (1) | GB9806449D0 (xx) |
HU (1) | HU225644B1 (xx) |
NO (1) | NO327609B1 (xx) |
NZ (1) | NZ507077A (xx) |
PL (1) | PL196076B1 (xx) |
PT (1) | PT1066376E (xx) |
WO (1) | WO1999049026A1 (xx) |
ZA (1) | ZA200004987B (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
NZ527036A (en) * | 2001-01-18 | 2005-03-24 | Univ Newcastle Ventures Ltd | Biosensor or protein array comprising a membrane-spanning protein and a lipid membrane formed from amphiphilic molecules and membrane-spanning protein molecules |
GB0121998D0 (en) | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
US7357935B2 (en) * | 2003-05-14 | 2008-04-15 | Wyeth | Avian E. coli vaccine for protection against colibacillosis |
US7297338B2 (en) * | 2003-05-14 | 2007-11-20 | Wyeth | Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella |
CN101378780A (zh) * | 2006-02-01 | 2009-03-04 | Sbl疫苗公司 | 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原 |
JP2008054614A (ja) * | 2006-09-01 | 2008-03-13 | Nippon Inst For Biological Science | 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター |
EP2066339B1 (en) * | 2006-09-18 | 2014-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
AU2008318615A1 (en) * | 2007-10-30 | 2009-05-07 | Texas A&M University System | Compositions and methods of enhancing immune responses to flagellated bacterium |
PT3097926T (pt) * | 2007-11-01 | 2020-01-08 | Univ Guelph | Composições e métodos de potenciação das respostas imunitárias frente a eimeria |
WO2011091255A1 (en) | 2010-01-21 | 2011-07-28 | The Board Of Trustees Of The University Of Arkansas | Vaccine vectors and methods of enhancing immune responses |
WO2011156619A2 (en) | 2010-06-09 | 2011-12-15 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
WO2014037445A1 (en) * | 2012-09-05 | 2014-03-13 | Lohmann Animal Health Gmbh | Preparation of live vaccines |
PL2929058T3 (pl) | 2012-12-07 | 2018-11-30 | Lohmann Animal Health Gmbh | Wytwarzanie żywych szczepionek |
CN105142665A (zh) | 2013-02-14 | 2015-12-09 | 阿肯色大学评议会 | 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法 |
US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
KR20230070521A (ko) | 2016-05-03 | 2023-05-23 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8730037D0 (en) | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
GB8912330D0 (en) | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
DE69012784D1 (de) * | 1990-02-06 | 1994-10-27 | Pasteur Institut | Transformiertes Shigella. |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
ES2131069T3 (es) * | 1991-03-05 | 1999-07-16 | Wellcome Found | Expresion de proteinas recombinantes en bacterias atenuadas. |
-
1998
- 1998-03-25 GB GBGB9806449.6A patent/GB9806449D0/en not_active Ceased
-
1999
- 1999-03-25 WO PCT/GB1999/000935 patent/WO1999049026A1/en active IP Right Grant
- 1999-03-25 EP EP99911949A patent/EP1066376B1/en not_active Expired - Lifetime
- 1999-03-25 AU AU30458/99A patent/AU763683B2/en not_active Ceased
- 1999-03-25 PL PL343246A patent/PL196076B1/pl not_active IP Right Cessation
- 1999-03-25 DE DE69925585T patent/DE69925585T2/de not_active Expired - Lifetime
- 1999-03-25 PT PT99911949T patent/PT1066376E/pt unknown
- 1999-03-25 DK DK99911949T patent/DK1066376T3/da active
- 1999-03-25 AT AT99911949T patent/ATE296881T1/de active
- 1999-03-25 KR KR1020007010633A patent/KR100628657B1/ko not_active IP Right Cessation
- 1999-03-25 CA CA2323576A patent/CA2323576C/en not_active Expired - Fee Related
- 1999-03-25 HU HU0105430A patent/HU225644B1/hu not_active IP Right Cessation
- 1999-03-25 US US09/646,925 patent/US6902906B1/en not_active Expired - Fee Related
- 1999-03-25 CZ CZ20003470A patent/CZ301520B6/cs not_active IP Right Cessation
- 1999-03-25 JP JP2000537987A patent/JP4516210B2/ja not_active Expired - Fee Related
- 1999-03-25 NZ NZ507077A patent/NZ507077A/xx unknown
- 1999-03-25 ES ES99911949T patent/ES2244182T3/es not_active Expired - Lifetime
-
2000
- 2000-09-19 ZA ZA200004987A patent/ZA200004987B/en unknown
- 2000-09-25 NO NO20004781A patent/NO327609B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1999049026A1 (en) | 1999-09-30 |
GB9806449D0 (en) | 1998-05-27 |
JP2002507414A (ja) | 2002-03-12 |
CZ301520B6 (cs) | 2010-03-31 |
AU763683B2 (en) | 2003-07-31 |
ZA200004987B (en) | 2001-10-31 |
US6902906B1 (en) | 2005-06-07 |
ES2244182T3 (es) | 2005-12-01 |
PL196076B1 (pl) | 2007-12-31 |
CA2323576C (en) | 2010-12-07 |
CA2323576A1 (en) | 1999-09-30 |
HUP0105430A3 (en) | 2004-10-28 |
AU3045899A (en) | 1999-10-18 |
NO20004781D0 (no) | 2000-09-25 |
HUP0105430A2 (hu) | 2002-04-29 |
EP1066376B1 (en) | 2005-06-01 |
EP1066376A1 (en) | 2001-01-10 |
KR100628657B1 (ko) | 2006-09-26 |
PL343246A1 (en) | 2001-07-30 |
NZ507077A (en) | 2002-10-25 |
HU225644B1 (en) | 2007-05-02 |
PT1066376E (pt) | 2005-10-31 |
JP4516210B2 (ja) | 2010-08-04 |
NO20004781L (no) | 2000-11-08 |
CZ20003470A3 (cs) | 2001-07-11 |
DE69925585D1 (de) | 2005-07-07 |
DK1066376T3 (da) | 2005-10-03 |
DE69925585T2 (de) | 2006-07-13 |
ATE296881T1 (de) | 2005-06-15 |
KR20010042175A (ko) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002521345A (ja) | 鳥類病原体を制御するため生きた弱毒化サルモネラワクチン | |
NO327609B1 (no) | Svekkede muterte bakterier anvendelige i vaksiner. | |
CA2244807A1 (en) | Salmonella typhimurium vaccine | |
Barnoy et al. | Characterization of WRSs2 and WRSs3, new second-generation virG (icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity | |
DK2879700T3 (en) | Hitherto unknown live attenuated Shigella vaccine | |
Ahmed et al. | Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y | |
Venkatesan et al. | Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine | |
Dilts et al. | Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity | |
Su et al. | Regulated delayed Shigella flexneri 2a O-antigen synthesis in live recombinant Salmonella enterica serovar Typhimurium induces comparable levels of protective immune responses with constitutive antigen synthesis system | |
Newland et al. | Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen | |
Mills et al. | Analysis and genetic manipulation of Shigella virulence determinants for vaccine development | |
US6905691B1 (en) | Vaccines containing attenuated bacteria | |
US20230372462A1 (en) | High dose shigella vaccine preparation | |
EP1037664A1 (en) | Vaccines containing attenuated bacteria | |
MXPA00009354A (en) | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |